Bristol Myers Squibb, a global biopharmaceutical company, completed the acquisition of Mirati Therapeutics, a commercial stage biotechnology company, for $4.7bn. “The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in the latter half of the decade and beyond. Mirati’s incredibly talented employees have built a strong portfolio of assets and capabilities that are highly complementary with BMS’. We welcome them and look forward to working together to leverage BMS’ global scale and resources to deliver more treatments for cancer patients, faster," Chris Boerner, Bristol Myers CEO.